Format

Send to

Choose Destination
Trends Cancer. 2017 Jun;3(6):454-469. doi: 10.1016/j.trecan.2017.04.002. Epub 2017 May 14.

Targeting PI3K Signaling in Combination Cancer Therapy.

Author information

1
Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier, Toulouse, France; Laboratoire d'Excellence LABEX TouCAN, Toulouse, France.
2
Centre de Recherches en Cancérologie de Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III Paul Sabatier, Toulouse, France; Laboratoire d'Excellence LABEX TouCAN, Toulouse, France. Electronic address: julie.guillermet@inserm.fr.

Abstract

Targeting upstream phosphatidylinositol-3-kinases (PI3Ks) in the PI3K/Akt/mTOR pathway appears to be a promising therapy in solid cancers; however, first early clinical trials with PI3K inhibitors in monotherapy have been disappointing. A massive array of preclinical and clinical trials are currently evaluating combinations of PI3K inhibitors in targeted therapies. These combinations include co-treatments with drugs directed against other intra-/extracellular signaling molecules, nuclear hormone receptors, DNA damage repair enzymes, and immune modulators. We review the literature and pinpoint mechanisms of action in different genomic and organ contexts. Combinatorial approaches are potentially superior to monotherapies and should become alternative clinical strategies to treat cancer patients.

KEYWORDS:

PI3K inhibitors; cell signaling; early Phase I trial; hormone therapies; liquid biopsies; targeted therapies

PMID:
28718419
DOI:
10.1016/j.trecan.2017.04.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center